• NeuroSense flagged plans to file a New Drug Submission with Health Canada for PrimeC in ALS in coming months.
• Regulatory path follows a pre-submission meeting, supported by Phase 2b PARADIGM results.
• PARADIGM met its primary TDP-43 biomarker endpoint (p=0.0421); survival analysis showed a 14.9-month median benefit (HR 0.35; p=0.0037).
• Announcement posted at https://www.neurosense-tx.com/.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN09247) on July 22, 2026, and is solely responsible for the information contained therein.